Linked Life Data

3948191

Source:http://linkedlifedata.com/resource/pubmed/id/3948191

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1986-4-4
pubmed:abstractText
Thirty-four patients with advanced or recurrent mixed mesodermal sarcoma of the uterus were entered in a study of single-agent cisplatin as second-line chemotherapy at a dose of 50 mg/m2 iv every 3 weeks. Twenty-eight of the 34 patients had mixed mesodermal sarcomas and measurable disease and had received one or more courses of the drug. Of these patients, five (18%) had objective response to therapy. Two patients who developed clinical complete response had long progression-free intervals (14 and 16 months) and remained alive at 21 and 36 months after initiation of therapy. Adverse effects were those described in a number of series employing cisplatin and were tolerable. Cisplatin thus appears to have definite activity as a second-line agent in the treatment of mixed mesodermal sarcomas of the uterus.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0361-5960
pubmed:author
pubmed:issnType
Print
pubmed:volume
70
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
271-4
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.